Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Neurosyphilis Indication Strategy Report 2026: Penicillin-binding protein, Trials and Deals
3 August 2026
2026 Neurosyphilis indication strategy covering epidemiology, Penicillin-binding protein biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital syphilis Indication Strategy Report 2026: Penicillin-binding protein, Trials and Deals
3 August 2026
2026 Congenital syphilis indication strategy covering epidemiology, Penicillin-binding protein biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Disseminated gonococcal infection Indication Strategy Report 2026: DNA gyrase, Trials and Deals
3 August 2026
2026 Disseminated gonococcal infection indication strategy covering epidemiology, DNA gyrase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Leprosy Indication Strategy Report 2026: RNA polymerase, Trials and Deals
3 August 2026
2026 Leprosy indication strategy covering epidemiology, RNA polymerase biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Latent tuberculosis infection Indication Strategy Report 2026: Mtb antigen, Trials and Deals
3 August 2026
2026 Latent tuberculosis infection indication strategy covering epidemiology, Mtb antigen biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Multidrug-resistant tuberculosis Indication Strategy Report 2026: DprE1, Trials and Deals
3 August 2026
2026 Multidrug-resistant tuberculosis indication strategy covering epidemiology, DprE1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Extensively drug-resistant tuberculosis Indication Strategy Report 2026: DprE1, Trials and Deals
3 August 2026
2026 Extensively drug-resistant tuberculosis indication strategy covering epidemiology, DprE1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Buruli ulcer Indication Strategy Report 2026: RNA polymerase, Trials and Deals
3 August 2026
2026 Buruli ulcer indication strategy covering epidemiology, RNA polymerase biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
NCT07705334 SHY-ONC6 Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07705334 clinical trial report covering SHY-ONC6, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262697 Dienogest Endometriosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262697 clinical trial report covering Dienogest, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07704515 GKL-006Allo Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07704515 clinical trial report covering GKL-006Allo, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128204 FB-7013 Glomerulonephritis, IGA Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128204 clinical trial report covering FB-7013, Phase 1, endpoints, sponsor, geography, readout timing and development white space.